Cohlhepp Ryan 4
4 · Bicara Therapeutics Inc. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Bicara (BCAX) President Ryan Cohlhepp Exercises Options, Sells Shares
What Happened
Ryan Cohlhepp, President & COO and a director of Bicara Therapeutics (BCAX), exercised stock options and sold company shares on May 15, 2026. The filing shows an exercise (M) to acquire 8,000 shares at $3.79 per share (cost $30,318), and open‑market sales of 8,000 and 4,500 shares at a weighted average sale price of $20.29 (combined gross proceeds $162,335 + $91,314 = $253,649). The report also lists an M‑coded disposition of 8,000 shares at $0 (see Key Details / footnote for vesting info).
Key Details
- Transaction date: 2026-05-15; Form 4 filed 2026-05-18 (no late‑filing flag in the provided data).
- Exercise: 8,000 shares acquired at $3.79 per share (total cost $30,318).
- Sales: 12,500 shares sold in open market at weighted average $20.29 per share (total proceeds $253,649). Footnote reports sale prices ranged $20.08–$20.62.
- Additional line: an M‑coded disposition of 8,000 shares recorded at $0 (derivative); Footnote 3 notes the underlying option vests in 16 equal quarterly installments beginning Aug 8, 2023.
- Footnote 1: sales were executed pursuant to a Rule 10b5‑1 trading plan adopted Feb 12, 2025.
- Shares owned after the transactions: not specified in the provided excerpt.
Context
The sequence—option exercise and same‑day open‑market sales—means Cohlhepp converted options into shares and sold shares on the same date. The presence of a Rule 10b5‑1 plan indicates the sales were prearranged. The filing is factual and does not speak to the insider’s motives.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-15$3.79/sh+8,000$30,318→ 204,141 total - Sale
Common Stock
[F1][F2]2026-05-15$20.29/sh−8,000$162,335→ 196,141 total - Sale
Common Stock
[F1][F2]2026-05-15$20.29/sh−4,500$91,314→ 191,641 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-05-15−8,000→ 101,334 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (8,000 underlying)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.